Home › Trials › NCT04100174
Clinical trial Recruiting at 2 sites Phase 2 Interventional Men only

Focal brachytherapy boost combined with stereotactic radiotherapy for prostate cancer

Official title: Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy

Run by Centre hospitalier de l'Université de Montréal (CHUM) · NCT04100174 · Data updated 2026-11-12

This study is testing a new combination treatment for prostate cancer to see if it causes less urinary problems and improves quality of life compared to standard care.

Quick facts

PhasePhase 2
Study typeInterventional
SexMen only
Enrollment150 (estimated)
SponsorCentre hospitalier de l'Université de Montréal (CHUM)
Academic / other
Locations2 sites (Montreal, Quebec and 1 other locations)
StatusRecruiting
StartedJuly 1, 2019
Main results expectedMay 30, 2025
Study endsJune 30, 2025
Registry record updatedMarch 13, 2025
Trial IDNCT04100174 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men with histologically confirmed prostate cancer who are eligible for curative-intent HDR brachytherapy boost to external beam radiotherapy.

Probably not a fit

Patients with extensive disease affecting more than 50% of the prostate gland may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II trial aims to evaluate the effectiveness of a focal brachytherapy (fBT) boost combined with stereotactic radiotherapy (sRT) in treating prostate cancer. The study compares this approach to standard care, focusing on urinary toxicity and quality of life outcomes. Participants will be monitored for changes in urinary irritation and obstruction over a period of 12 to 24 months using electronic patient-reported outcomes. The goal is to determine if the new treatment method results in fewer patients experiencing significant declines in urinary quality of life.

Why it matters

Potential benefit: If successful, this treatment could lead to reduced urinary side effects for prostate cancer patients undergoing radiotherapy.

How similar studies have gone: Other studies have explored similar approaches, but this specific combination of treatments is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
* ECOG 0-1
* Charlson Comorbidity Index ≤ 4
* Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.

Exclusion - none

Where it's running

  • Centre Hospitalier de l'Université de Montréal
    Montreal, Quebec, Canada     Recruiting
  • Chuq
    Québec, Quebec, Canada     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Centre hospitalier de l'Université de Montréal (CHUM) 72
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.